Exciting news! We’ve completed enrollment of 188 patients with colorectal cancer in our DeFianCe Phase 2 study of DKN-01 with bev and chemo. Huge thanks to our patients and global care teams! Stay tuned for initial results in mid-2025.
关于我们
Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. For more information about Leap Therapeutics, visit https://www.leaptx.com or our public filings with the SEC that are available via EDGAR at https://www.sec.gov or via https://www.investors.leaptx.com.
- 网站
-
https://www.leaptx.com
Leap Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge，MA
- 类型
- 上市公司
地点
-
主要
获取路线
47 Thorndike St, Suite B1-1
US，MA，Cambridge，02141
Leap Therapeutics员工
动态
-
At Leap Therapeutics, we believe that teamwork is the foundation of our success. Whether we’re deep in research, collaborating on strategies, or enjoying a fun scavenger hunt to recharge, our Leapsters show relentless dedication and support for one another. It's through hard work, shared goals, and the friendships we’ve built that we continue to make a meaningful impact on cancer patients’ lives. Together, we’re not just colleagues – we’re a team driving change.
-
-
The #Leapsters had a great time during our summer outing at Spin sharpening our ping pong skills!??
-
-
We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world. https://lnkd.in/dj5gBmkF
Leap Therapeutics Announces $40 Million Private Placement | Leap Therapeutics, Inc.
investors.leaptx.com
-
March is Colorectal Cancer Awareness Month. Through our DeFianCe Phase 2 CRC clinical trial, we're reminded of the unmet medical need of these patients and the dedication from our clinical sites and physicians aiming for better outcomes. https://lnkd.in/e3S8CwVj
Colorectal Cancer
https://www.leaptx.com
-
Reminder to join Drs. Pelster & Wainberg today at 8:30 AM ET, for their firsthand accounts on DeFianCe, our 2L CRC trial of DKN-01 in combination with Bevacizumab and chemo. Link here: https://lnkd.in/ejiqtJ-9
-
Join us at ASCO GI 2024 for updates on Part A of our DeFianCe #colorectalcancer study at Moscone West on Jan 20th from 6:30-9:30AM PST at poster G8. Also, tune in on Jan 23, 8:30 am ET to hear insights from the treating physicians. Details and links:
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium | Leap Therapeutics, Inc.
investors.leaptx.com
-
Join us at J.P. Morgan’s 42nd Annual Healthcare Conference, 1/10/24, 1:30pm PT, to hear from our CEO Doug Onsi on Leap and our lead program, DKN-01. #JPM2024 https://lnkd.in/eemgN4wZ
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference | Leap Therapeutics, Inc.
investors.leaptx.com